Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05042128
Title The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (ASCEND)
Acronym ASCEND
Recruitment Active, not recruiting
Gender
Phase Phase II
Variant Requirements No
Sponsors Australasian Gastro-Intestinal Trials Group
Indications
Therapies
Age Groups: senior | adult
Covered Countries NZL | AUS


No variant requirements are available.